A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies (Q33735754)

29 July 2017

title

A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies (English)

1 reference

29 July 2017

13

Olivier Rixe

1 reference

29 July 2017

Trisha M Wise-Draper

1

1 reference

29 July 2017

Ganesh Moorthy

2

1 reference

29 July 2017

Mohamad A Salkeni

3

1 reference

29 July 2017

Nagla Abdel Karim

4

1 reference

29 July 2017

Hala Elnakat Thomas

5

1 reference

29 July 2017

Carol A Mercer

6

1 reference

29 July 2017

M Shalaan Beg

7

1 reference

29 July 2017

Sue O'Gara

8

1 reference

29 July 2017

Olugbenga Olowokure

9

1 reference

29 July 2017

Hassana Fathallah

10

1 reference

29 July 2017

Sara C Kozma

11

1 reference

29 July 2017

George Thomas

12

1 reference

29 July 2017

Pankaj Desai

14

1 reference

29 July 2017

John C Morris

15

1 reference

29 July 2017

publication date

29 March 2017

1 reference

29 July 2017

1 reference

29 July 2017

volume

12

1 reference

29 July 2017

issue

3

1 reference

29 July 2017

page(s)

323-332

1 reference

Creative Commons Attribution-NonCommercial 4.0 International

29 July 2017

copyright license

start time

29 March 2017

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Everolimus for advanced pancreatic neuroendocrine tumors.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

mTOR and cancer: insights into a complex relationship

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Strategies for optimizing combinations of molecularly targeted anticancer agents

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Pharmacokinetic interaction between verapamil and everolimus in healthy subjects

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Clinical pharmacokinetics of everolimus

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Phosphoinositide 3-kinase signalling--which way to target?

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Toxicity and response criteria of the Eastern Cooperative Oncology Group

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5447332

Phase I study of everolimus in pediatric patients with refractory solid tumors

14 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S11523-017-0482-9

Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007/S11523-017-0482-9

Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28357727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Absorption and intestinal metabolism of SDZ-RAD and rapamycin in rats

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28357727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Everolimus drug interactions: application of a classification system for clinical decision making

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28357727

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S11523-017-0482-9

1 reference

Dimensions Publication ID

29 July 2017

0 references

1 reference

29 July 2017

1 reference